Skip to main content

Advertisement

Log in

The levels of serum-soluble Fas in patients with rheumatoid arthritis and systemic sclerosis

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Different defects in Fas/APO-1 interaction with its ligand or in signaling of apoptosis may contribute to autoimmune disease. The aim of this study was to examine whether elevated serum-soluble Fas (sFas) levels are associated with rheumatoid arthritis (RA) or systemic sclerosis (SSc). sFas level was assayed using a sandwich ELISA in serum from 37 patients with RA, 30 patients with SSc and 20 healthy controls. The RA patients were classified according to disease activity, anatomical joint damage, and the presence of pulmonary involvement. Presence of pulmonary fibrosis, CO diffusion capacity (DLCO) and skin score were determined in patients with SSc. Serum sFas levels were not significantly different between study groups. Serum sFas level in the active RA patients was significantly higher than in the patients with inactive disease (p<0.05). The untreated active RA patients had significantly higher sFas level than healthy controls (p<0.05). In RA patients, sFas level was significantly correlated with rheumatoid factor titer (p=0.01), C-reactive protein (p<0.05), and erythrocyte sedimentation rate (p<0.05). The RA patients with severe joint damage had significantly higher sFas level than those with mild joint damage (p<0.05). The untreated SSc patients had significantly higher sFas levels than the treated SSc patients and healthy controls (p<0.01). Serum sFas level was not correlated with presence of pulmonary fibrosis, DLCO or skin score. The soluble Fas molecule may provide a useful additional marker for assessment of disease activity and severity in patients with RA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

CRP:

C-reactive protein

DLCO:

CO diffusion capacity

ESR:

Erythrocyte sedimentation rate

RA:

Rheumatoid arthritis

RF:

Rheumatoid factor

sFas:

Serum-soluble Fas

SSc:

Systemic sclerosis

References

  1. Mountz JD, Wu J, Cheng J, Zhou T (1994) Autoimmune disease: A problem of defective apoptosis. Arthritis Rheum 37: 1415–1420

    Google Scholar 

  2. Williams GT (1994) Apoptosis in the immune system. J Pathol 173: 1–4

    CAS  PubMed  Google Scholar 

  3. Krammer PH, Behrmann I, Daniel P, Dhein J, Debatin KM (1994) Regulation of apoptosis in the immune system. Curr Opin Immunol 6: 279–289

    CAS  PubMed  Google Scholar 

  4. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S (1992) Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356: 314–317

    CAS  PubMed  Google Scholar 

  5. Adachi M, Watanaba-Fukunaga R, Nagata S (1993) Aberrant transcription caused by the insertion of an early transposable element in an intron of the Fas antigen gene of lpr mice. Proc Natl Acad Sci USA 90: 1756–1761

    CAS  PubMed  Google Scholar 

  6. Nagata S, Suda T (1995) Fas and Fas-ligand: lpr and gld mutations. Immunol Today 16: 39–43

    Article  CAS  PubMed  Google Scholar 

  7. Cheng J, Zhou T, Liu C et al. (1994) Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263: 1759–1762

    CAS  PubMed  Google Scholar 

  8. Mysler E, Bini P, Drappa J et al. (1994) The apoptosis-1/Fas protein in human systemic lupus erythematosus. J Clin Invest 93: 1029–1034

    CAS  PubMed  Google Scholar 

  9. Nozawa K, Kayagaki N, Tokano Y, Yagita H, Okumura K, Hasimoto H (1997) Soluble Fas (APO-1, CD95) and soluble Fas Ligand in rheumatic diseases. Arthritis Rheum 40: 1126–1129

    Google Scholar 

  10. Nakajima T, Aono H, Hasunuma T et al. (1995) Apoptosis and functional Fas antigen in rheumatoid arthritis synoviocytes. Arthritis Rheum 38: 485–491

    Google Scholar 

  11. Firestein G, Yeo M, Zvaifler N (1995) Apoptosis in rheumatoid arthritis synovium. J Clin Invest 96: 1631–1638

    CAS  PubMed  Google Scholar 

  12. Hasunuma T, Kayagaki N, Asahara H et al. (1997) Accumulation of soluble Fas in inflamed joints of patients with rheumatoid arthritis. Arthritis Rheum 40: 80–86

    Google Scholar 

  13. Hasunuma T, Hoa TTM, Aono H et al. (1996) Induction of Fas-dependent apoptosis in synovial infiltrating cells in rheumatoid arthritis. Int Immunol 8: 1595–1602

    CAS  PubMed  Google Scholar 

  14. Kahari VM (1993) Activation of dermal connective tissue in scleroderma. Ann Med 25: 511–518

    PubMed  Google Scholar 

  15. Sgonc R, Gruschwitz MS, Dietrich H, Recheis H, Gershwin ME, Wick G (1996) Endothelial cell apoptosis is a primary pathogenic event underlying skin lesions in avian and human scleroderma. J Clin Invest 98: 785–792

    CAS  PubMed  Google Scholar 

  16. Roumm AD, Whiteside TL, Medsger TA Jr, Rodnan GP (1984) Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum 27: 645–653

    Google Scholar 

  17. Gustaffsson R, Tötterman TH, Klareskog L, Hallgren R (1990) Increase in activated T cells and reduction in suppressor inducer T cells in systemic sclerosis. Ann Rheum Dis 49: 40–49

    PubMed  Google Scholar 

  18. Needleman BW, Ordonez JV, Taramelli D, Alms W, Gayer K, Choi J (1990) In vitro identification of a subpopulation of fibroblasts that produces high levels of collagen in scleroderma patients. Arthritis Rheum 33: 842–852

    CAS  PubMed  Google Scholar 

  19. Arnett FC, Edworthy SM, Bloch DA et al. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31: 315–324

    CAS  PubMed  Google Scholar 

  20. Subcommittee for scleroderma criteria of the American Rheumatism Association diagnostic and therapeutic criteria committee (1980) Preliminary criteria for the classification of systemic sclerosis (Scleroderma). Arthritis Rheum 23: 581–590

    PubMed  Google Scholar 

  21. Pinals RS, Masi AT, Larsen RA (1981) Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 24: 1308–1315

    Google Scholar 

  22. Larsen A, Dale K, Eek M (1977) Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn 18: 481–491

    CAS  Google Scholar 

  23. Kahaleh MB, Sultany GI, Smith EA, Huffstutter JE, Loadholt B, LeRoy EC (1986) A modified scleroderma skin scoring method. Clin Exp Rheumatol 4: 367–369

    CAS  PubMed  Google Scholar 

  24. Christensson M, Pettersson E, Eneslatt K et al. (2002) Serum sFas levels are elevated in ANCA-positive vasculitis compared with other autoimmune diseases. J Clin Immunol 22: 220–227

    Article  CAS  PubMed  Google Scholar 

  25. Knipping E, Krammer PH, Onel KB, Lehman TJA, Mysler E, Elkon KB (1995) Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis. Arthritis Rheum 38: 1735–1737

    CAS  PubMed  Google Scholar 

  26. Goel N, Ulrich DT, Clair WS, Fleming JA, Lynch DH, Seldin MF (1995) Lack of correlation between serum soluble Fas/APO-1 levels and autoimmune disease. Arthritis Rheum 38: 1738–1743

    Google Scholar 

  27. Fujihara T, Takeuchi T, Tsubota K et al.(1998) Serum soluble Fas/APO-1 is increased in patients with primary Sjogren’s syndrome. Clin Rheumatol 17: 496–499

    CAS  PubMed  Google Scholar 

  28. Utz PJ, Anderson P (1998) Posttransplantation protein modifications, apoptosis, and the bypass of tolerance to autoantigens. Arthritis Rheum 41: 1152–1160

    Google Scholar 

  29. Hashimoto H, Tanaka M, Suda T et al. (1998) Soluble Fas ligand in the joints of patients with rheumatoid arthritis and osteoarthritis. Arthritis Rheum 41: 657–662

    Article  CAS  PubMed  Google Scholar 

  30. Wetzig T, Petri JB, Mittag M, Haustein UF (1998) Serum levels of soluble Fas/APO-1 receptor are increased in systemic sclerosis. Arch Dermatol Res 290: 187–190

    Article  CAS  PubMed  Google Scholar 

  31. Stummvoll GH, Aringer M, Smolen JS et al. (2000) Derangement of apoptosis-related lymphocyte homeostasis in systemic sclerosis. Rheumatology 39: 1341–1350

    Article  CAS  PubMed  Google Scholar 

  32. Tomokuni A, Aikoh T, Matsuki T et al.(1997) Elevated soluble Fas/APO-1 (CD95) levels in silicosis patients without clinical symptoms of autoimmune diseases or malignant tumours. Clin Exp Immunol 110: 303–309

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Aşkın Ateş.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ateş, A., Kinikli, G., Turgay, M. et al. The levels of serum-soluble Fas in patients with rheumatoid arthritis and systemic sclerosis. Clin Rheumatol 23, 421–425 (2004). https://doi.org/10.1007/s10067-004-0909-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-004-0909-4

Keywords

Navigation